with Larimar Therapeutics
on their CTI-1601 Program in FA
FARA and Larimar Therapeutics will host an informational webinar on the CTI-1601 Program in FA, on Thursday, September 22, 2022 at 7pm (ET), for the FA patient community. The presenter will be Larimar Chief Executive Officer, Dr. Carole Ben-Maimon; and the Q&A will be moderated by FARA CEO, Jen Farmer and Director of Patient Engagement, Layne Rodden.
This webinar will provide information on the CTI-1601 program including a review of the Phase I trial data, the recent partial lift of the FDA clinical hold, and plans for a Phase 2 dose exploration trial of CTI-1601 in Friedreich's ataxia patients. To read the recent press release from Larimar Therapeutics, click HERE. There will be time for Q&A. However, we encourage submission of questions in advance with your registration for the event. Register HERE for the webinar. Submit your questions HERE. After registering, you will receive a confirmation email with the link to join us.
Register for the Sessions
Submit Questions
Anyone considering participating in a clinical trial should discuss the matter with his or her physician. FARA does not endorse or recommend any particular studies.
